Skip to main content
Top
Published in: Clinical & Experimental Metastasis 7/2013

01-10-2013 | Research Paper

Gene silencing of c-Met leads to brain metastasis inhibitory effects

Authors: Se Jeong Lee, Ho Jun Seol, Hye Won Lee, Won Young Kang, Bong Gu Kang, Juyoun Jin, Mi-Young Jo, Younggeon Jin, Jung-Il Lee, Kyeung Min Joo, Do-Hyun Nam

Published in: Clinical & Experimental Metastasis | Issue 7/2013

Login to get access

Abstract

An unfortunate consequence of improvements in the treatments of advanced primary cancers is the concurrent increase of metastatic brain tumors. Despite of unfavorable clinical prognosis, radiation therapy is still the only viable treatment option for brain metastases. Expression of c-Met induces cell migration and invasion in many cancers, which are indispensable steps for metastasis. Accordingly, we examined the effects of gene silencing of c-Met on brain metastasis to evaluate the possibility of c-Met as a potential target. MDA-MB-435 cells were transfected with c-Met targeting short hairpin RNAs (shRNAs). Effects of c-Met shRNAs on the expression of epithelial mesenchymal transition (EMT) related proteins, in vitro migration, and in vivo brain metastasis were examined. Expression of mesenchymal markers and in vitro migration of MDA-MB-435 cells were significantly inhibited by introduction of c-Met shRNAs. When c-Met-silenced MDA-MB-435 cells were stereotactically implanted into the brains of immune-compromised mice or injected into the right internal carotid arteries, c-Met-silenced MDA-MB-435 cells produced significantly smaller tumor masses or survival time was significantly prolonged, respectively, compared with MDA-MB-435 cells transfected with control shRNA. The data reveal the novel function of c-Met in the process of brain metastasis and its potential as a preventive and/or therapeutic target in this disease.
Appendix
Available only for authorised users
Literature
2.
go back to reference Bladt F, Riethmacher D, Isenmann S et al (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768–771PubMedCrossRef Bladt F, Riethmacher D, Isenmann S et al (1995) Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 376:768–771PubMedCrossRef
3.
go back to reference Schmidt C, Bladt F, Goedecke S et al (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699–702PubMedCrossRef Schmidt C, Bladt F, Goedecke S et al (1995) Scatter factor/hepatocyte growth factor is essential for liver development. Nature 373:699–702PubMedCrossRef
4.
go back to reference Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925PubMedCrossRef Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF (2003) Met, metastasis, motility and more. Nat Rev Mol Cell Biol 4:915–925PubMedCrossRef
5.
go back to reference Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31:49–58PubMed Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Overexpression of c-Met and of the transducers PI3K, FAK and JAK in breast carcinomas correlates with shorter survival and neoangiogenesis. Int J Oncol 31:49–58PubMed
6.
go back to reference Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345–7355PubMed Christensen JG, Schreck R, Burrows J et al (2003) A selective small molecule inhibitor of c-Met kinase inhibits c-Met-dependent phenotypes in vitro and exhibits cytoreductive antitumor activity in vivo. Cancer Res 63:7345–7355PubMed
7.
go back to reference Hochgrafe F, Zhang L, O’Toole SA et al (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 70:9391–9401PubMedCrossRef Hochgrafe F, Zhang L, O’Toole SA et al (2010) Tyrosine phosphorylation profiling reveals the signaling network characteristics of Basal breast cancer cells. Cancer Res 70:9391–9401PubMedCrossRef
8.
go back to reference Previdi S, Maroni P, Matteucci E et al (2010) Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 46:1679–1691PubMedCrossRef Previdi S, Maroni P, Matteucci E et al (2010) Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 46:1679–1691PubMedCrossRef
9.
go back to reference Ponzo MG, Lesurf R, Petkiewicz S et al (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106:12903–12908PubMedCrossRef Ponzo MG, Lesurf R, Petkiewicz S et al (2009) Met induces mammary tumors with diverse histologies and is associated with poor outcome and human basal breast cancer. Proc Natl Acad Sci U S A 106:12903–12908PubMedCrossRef
10.
go back to reference Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-Cadherin promotes motility in human breast cancer cells regardless of their e-cadherin expression. J Cell Biol 147:631–643PubMedCrossRef Nieman MT, Prudoff RS, Johnson KR, Wheelock MJ (1999) N-Cadherin promotes motility in human breast cancer cells regardless of their e-cadherin expression. J Cell Biol 147:631–643PubMedCrossRef
11.
go back to reference Hazan RB, Phillips GR, Qiao RF et al (2000) Exogenous expression of n-cadherin in breast cancer cells induces cell migration, invasion, and meta. J Cell Biol 148:779–790PubMedCrossRef Hazan RB, Phillips GR, Qiao RF et al (2000) Exogenous expression of n-cadherin in breast cancer cells induces cell migration, invasion, and meta. J Cell Biol 148:779–790PubMedCrossRef
12.
go back to reference Shattuck DL, Miller JK, Carraway KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471–1477PubMedCrossRef Shattuck DL, Miller JK, Carraway KL, Sweeney C (2008) Met receptor contributes to trastuzumab resistance of Her2-overexpressing breast cancer cells. Cancer Res 68:1471–1477PubMedCrossRef
13.
go back to reference Benedettini E, Sholl LM, Peyton M et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415–423PubMedCrossRef Benedettini E, Sholl LM, Peyton M et al (2010) Met activation in non-small cell lung cancer is associated with de novo resistance to EGFR inhibitors and the development of brain metastasis. Am J Pathol 177:415–423PubMedCrossRef
14.
go back to reference Kong DS, Song SY, Kim DH et al (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115:140–148PubMedCrossRef Kong DS, Song SY, Kim DH et al (2009) Prognostic significance of c-Met expression in glioblastomas. Cancer 115:140–148PubMedCrossRef
15.
go back to reference Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214PubMedCrossRef Eder JP, Vande Woude GF, Boerner SA, LoRusso PM (2009) Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. Clin Cancer Res 15:2207–2214PubMedCrossRef
16.
go back to reference Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581PubMedCrossRef Rakha EA, Reis-Filho JS, Ellis IO (2008) Basal-like breast cancer: a critical review. J Clin Oncol 26:2568–2581PubMedCrossRef
17.
go back to reference Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537–544PubMedCrossRef Yehiely F, Moyano JV, Evans JR et al (2006) Deconstructing the molecular portrait of basal-like breast cancer. Trends Mol Med 12:537–544PubMedCrossRef
18.
go back to reference Goncalves A, Charafe-Jauffret E, Bertucci F et al (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420–1433PubMedCrossRef Goncalves A, Charafe-Jauffret E, Bertucci F et al (2008) Protein profiling of human breast tumor cells identifies novel biomarkers associated with molecular subtypes. Mol Cell Proteomics 7:1420–1433PubMedCrossRef
19.
go back to reference Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38:830–841PubMedCrossRef Garcia S, Dales JP, Charafe-Jauffret E et al (2007) Poor prognosis in breast carcinomas correlates with increased expression of targetable CD146 and c-Met and with proteomic basal-like phenotype. Hum Pathol 38:830–841PubMedCrossRef
20.
go back to reference Ponzo MG, Park M (2010) The met receptor tyrosine kinase and basal breast cancer. Cell Cycle 9:1043–1050PubMedCrossRef Ponzo MG, Park M (2010) The met receptor tyrosine kinase and basal breast cancer. Cell Cycle 9:1043–1050PubMedCrossRef
21.
go back to reference Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023PubMedCrossRef Turner N, Lambros MB, Horlings HM et al (2010) Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 29:2013–2023PubMedCrossRef
22.
go back to reference Schneider BP, Winer EP, Foulkes WD et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018PubMedCrossRef Schneider BP, Winer EP, Foulkes WD et al (2008) Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 14:8010–8018PubMedCrossRef
23.
go back to reference Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef Lynch TJ, Bell DW, Sordella R et al (2004) Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129–2139PubMedCrossRef
24.
go back to reference Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef Paez JG, Janne PA, Lee JC et al (2004) EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497–1500PubMedCrossRef
Metadata
Title
Gene silencing of c-Met leads to brain metastasis inhibitory effects
Authors
Se Jeong Lee
Ho Jun Seol
Hye Won Lee
Won Young Kang
Bong Gu Kang
Juyoun Jin
Mi-Young Jo
Younggeon Jin
Jung-Il Lee
Kyeung Min Joo
Do-Hyun Nam
Publication date
01-10-2013
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 7/2013
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-013-9584-7

Other articles of this Issue 7/2013

Clinical & Experimental Metastasis 7/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine